Clinical Trials for Ovarian Transitional Cell Carcinoma | Kisho | Kisho

Back to Ovarian Transitional Cell Carcinoma

Ovarian Transitional Cell Carcinoma — Clinical Trials

MONDO:00063439 active·1 recruitingLast updated: Mar 17, 2026, 1:09 PM

Trial Landscape

Ovarian Transitional Cell Carcinoma has a growing clinical research program, driven by procedure and drug treatment.

1

Recruiting

9

Active Trials

By Approach

Procedure8

Drug Treatment7

Biological Therapy5

5 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 1

2

Phase 2

4

Phase 3

5

Sponsor Types

NIH7Academic/Other2

Trial Locations

United States9 trials

South Korea4 trials

Canada4 trials

Japan3 trials

Puerto Rico2 trials

Italy1 trial

Mexico1 trial

Netherlands1 trial

Guam1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

9 Trials

Phase 3Recruiting

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Aug 2020Est. completion: Dec 2028Updated: Mar 2026

Phase 3Active, Not Recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Sep 2010Est. completion: Jul 2026Updated: Mar 2026

Phase 3Active, Not Recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2016Est. completion: Nov 2026Updated: Mar 2026

Phase 3Active, Not Recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2007Est. completion: Jan 2028Updated: Dec 2025

Phase 2Active, Not Recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jan 2017Est. completion: May 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2016Est. completion: Dec 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jun 2021Est. completion: Nov 2026Updated: Mar 2026

Phase 1Active, Not Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2020Est. completion: Jun 2026Updated: Mar 2026

Phase 1Active, Not Recruiting

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Sponsor:Mayo Clinic

United StatesStarted: Apr 2014Est. completion: Sep 2026Updated: Nov 2025

Stay informed about clinical trials for Ovarian Transitional Cell Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 17, 2026 at 1:09 PM